Parameter
| Biomarker | CEA (carcinoembryonic antigen) | Full name | Carcinoembryonic antigen | Molecular Type | Protein |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Diagnosis, prognosis, and monitoring | ||
| Disease | Gastric Cancer | Disease Subtypes | / | ||
| Organ | Stomach | Test Sample / Technology Platform | Serum (ELISA, chemiluminescence immunoassay), tumor tissue (IHC) | ||
| Pathobiological Mechanisms | The glycoprotein expressed in embryonic stage is low in normal adult tissues and re-expressed in gastric cancer due to abnormal cell proliferation. It is involved in tumor cell adhesion, invasion and angiogenesis. Its level is positively correlated with tumor burden, lymph node metastasis and distant metastasis risk, and can reflect treatment response and recurrence | ||||
| Clinical Availability Status | Clinical availability (auxiliary diagnosis/prognostic evaluation) : Routine clinical tests, used alone, have limited diagnostic sensitivity (4.3%-30%) and specificity, and are often combined with other markers | ||||
| Notes and Dynamics | Classic broad-spectrum tumor markers, which are widely used in the efficacy monitoring and recurrence warning of gastric cancer, can significantly improve the diagnostic accuracy when combined with CA19-9 and CA72-4. They are one of the most basic auxiliary indicators in clinical practice, but their diagnostic value for early gastric cancer is low | ||||